Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer
Public ClinicalTrials.gov record NCT05257408. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3 Study of Relacorilant in Combination With Nab-Paclitaxel Versus Nab-Paclitaxel Monotherapy in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (ROSELLA)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objectives of this study are to evaluate progression-free survival (PFS) by blinded independent central review (BICR) and overall survival (OS) (evaluated independently, as dual primary endpoints) in patients treated with intermittent regimen of relacorilant in combination with nab-paclitaxel compared with patients treated with nab-paclitaxel monotherapy.
Study identification
- NCT ID
- NCT05257408
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 381 participants
Conditions and interventions
Interventions
- Relacorilant 150 mg Drug
- Nab-paclitaxel 80 mg/m^2 Drug
- Nab-paclitaxel 100 mg/m^2 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 29, 2022 (Actual)
- Primary completion
- Mar 31, 2025 (Actual)
- Completion
- Dec 2026 (Estimated)
- Last update posted
- Sep 25, 2026
2022 – 2026
United States locations
- U.S. sites
- 44
- U.S. states
- 21
- U.S. cities
- 38
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site 318 | Phoenix | Arizona | 85016 | — |
| Site 277 | Tucson | Arizona | 85719 | — |
| Site 350 | Irvine | California | 92618 | — |
| Site 364 | La Jolla | California | 92093 | — |
| Site 150 | Palo Alto | California | 94304 | — |
| Site 278 | San Francisco | California | 94109 | — |
| Site 014 | San Francisco | California | 94143 | — |
| Site 316 | Solvang | California | 93463 | — |
| Site 032 | Aurora | Colorado | 80045 | — |
| Site 335 | Miami Beach | Florida | 33140 | — |
| Site 042 | Weston | Florida | 33331 | — |
| Site 009 | Atlanta | Georgia | 30322 | — |
| Site 272 | Atlanta | Georgia | 30342 | — |
| Site 372 | Gainesville | Georgia | 30548 | — |
| Site 291 | Savannah | Georgia | 31405 | — |
| Site 315 | Evanston | Illinois | 60201 | — |
| Site 314 | Hinsdale | Illinois | 60521 | — |
| Site 346 | Urbana | Illinois | 61801 | — |
| Site 339 | Indianapolis | Indiana | 46260 | — |
| Site 200 | Overland Park | Kansas | 66211 | — |
| Site 334 | Overland Park | Kansas | 66211 | — |
| Site 279 | Louisville | Kentucky | 40241 | — |
| Site 128 | Boston | Massachusetts | 02114 | — |
| Site 288 | New Brunswick | New Jersey | 08901 | — |
| Site 292 | Albuquerque | New Mexico | 87131 | — |
| Site 275 | Flushing | New York | 11355 | — |
| Site 298 | Cincinnati | Ohio | 45242 | — |
| Site 304 | Cincinnati | Ohio | 45459 | — |
| Site 280 | Portland | Oregon | 97210 | — |
| Site 317 | Portland | Oregon | 97213 | — |
| Site 049 | Portland | Oregon | 97239 | — |
| Site 337 | Bethlehem | Pennsylvania | 18015 | — |
| Site 127 | Pittsburgh | Pennsylvania | 15213 | — |
| Site 276 | Rapid City | South Dakota | 57701 | — |
| Site 368 | Germantown | Tennessee | 38138 | — |
| Site 281 | Nashville | Tennessee | 37203 | — |
| Site 229 | Austin | Texas | 78731 | — |
| Site 312 | Bedford | Texas | 76022 | — |
| Site 297 | Fort Worth | Texas | 76104 | — |
| Site 392 | San Antonio | Texas | 78240 | — |
| Site 301 | The Woodlands | Texas | 77380 | — |
| Site 300 | Norfolk | Virginia | 23502 | — |
| Site 365 | Richmond | Virginia | 23298 | — |
| Site 121 | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 72 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05257408, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 25, 2026 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05257408 live on ClinicalTrials.gov.